SETD2 loss creates BCL‑xL dependency in kidney cancer, suggesting new treatment
Medical Xpress1 min read110 words
A common genetic mutation that helps some kidney cancers survive may also expose an unexpected weakness, one that MUSC Hollings Cancer Center researchers hope to transform into a new treatment strategy. In a study published in Cancer Research, Aguirre de Cubas, Ph. D., and colleagues have discovered that kidney cancer cells lacking the tumor suppressor gene SETD2 become highly dependent on a protein called BCL-xL for survival. By targeting that dependency, the researchers were able to selectively eliminate SETD2-deficient cancer cells in laboratory models while largely sparing cancer cells with intact SETD2. The findings identify a potential new therapeutic strategy for patients with a particularly aggressive subset of kidney cancers.
🤖 AI-generated content — This article was automatically summarised from public RSS feeds by AutoBrief. Verify important information with the original source.